Edgar Filing: CHAMPIONS BIOTECHNOLOGY, INC.

Unassociated Document


	OMB APPROVAL
	OMB Number: 3235-0145
	Expires: February 28, 2009
	Estimated average burden hours per response. . . . . . . .14.5

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Champions Biotechnology, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

158704304

(CUSIP Number)

Dr. David Sidransky, 1550 Orleans Street, Baltimore, Maryland 21231

(Name, Address and Telephone Number of Person Aut horized to

Receive Notices and Communications)

May 18, 2007

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (åActæ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No. 158704304

1.	Names of Reporting Persons.
	I.R.S. Identification Nos. of above persons (entities only).

	David Sidransky

2.	Check the Appropriate Box if a Member of< /font> a Group (See Instructions)

	(a)

	(b)	o

3.	SEC Use Only

4.	Source of Funds (See Instructions) 00

5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)	o

6.	Citizenship or Place of Organization United States



Number of	7.	Sole Voting Power 10,800,000
Shares Bene-
ficially by	8.	Shared Voting Power
Owned by Each
Reporting	9.	Sole Dispositive Power 10,800,000
Person With
	10.	Shared Dispositive Power

11.	Aggregate Amount Beneficially Owned by Each Reporting Person 10,800,000.

12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ...	o
13.	Percent of Class Represented by Amount in Row (11) 34.2%

14.	Type of Reporting Person (See Instructions)
	IN

Item 1. Security and Issuer

The class of equity securities to which this statement relates is the common stock, par value $0.001 per share, of Champions Biotechnology, Inc., a Delaware Corporation (the “Issuer”), whose principal executive office is located at 2200 Wilson Blvd, Suite 102-316, Arlington, Virginia 22201.

Item 2. Identity and Background

(a) Reporting Person: Dr. David Sidransky

(b) Address: 1550 Orleans Street, Baltimore, Maryland 21231

(d) Dr. Sidransky has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) Dr. Sidransky has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) Citizenship: United States

Item 3. Source and Amount of Funds or Other Consideration

On May 18, 2007, Dr. Sidransky received 3,800,000 restricted shares of Common Stock of the Issuer pursuant to an Agreement and Plan of Merger dated May 17, 2007, pursuant to which Biomerk, Inc., a private biotechnology company, merged with the Issuer’s wholly-owned subsidiary in a reverse triangular merger and became a wholly-owned subsidiary of the Issuer. In connection with the merger, Dr. Sidransky exchanged all of the shares of Common Stock of Biomerk, Inc. owned by him for the restricted shares of Common Stock of the Issuer.

Item 4. Purpose of Transaction

Dr. Sidransky acquired the Common Stock of the Issuer for investment purposes and has no definitive plan or proposal which may relate to or would result in:

(a) The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer;

(b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the issuer or any of its subsidiaries;

(d) Any change in the present board of directors or management of the issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(e) Any material change in the present capitalization or dividend policy of the issuer;

(f) Any other material change in the issuer’s business or corporate structure including but not limited to, if the issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment

policy for which a vote is required by section 13 of the Investment Company Act of 1940;

(g) Changes in the issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person;

(h) Causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(i) A class of equity securities of the issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(j) Any action similar to any of those enumerated above.

Item 5. Interest in Securities of the Issuer

Dr. Sidransky has beneficial ownership of 10,800,000 shares of Common Stock of the Issuer. He has sole power to vote and sole power to dispose or direct the disposition of these shares. These shares represent 34.2% of the outstanding shares of Common Stock (based in the Issuer’s Form 8-K filed on May 24, 2007). Dr. Sidransky has not engaged in any transactions in the Common Stock during the past sixty days. No person other than Dr. Sidransky has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by Dr. Sidransky.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

None.

Item 7. Material to Be Filed as Exhibits

No material is required to be filed as an exhibit hereto.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

May 29, 2007

Date

/s/ David Sidransky

Signature

Dr. David Sidransky

Name/Title

The original statement shall be signed by each person on whose behalf the statement is filed or his authorizedrepresentative. If the statement is signed on behalf of a person by his authorized representative (other than an executiveofficer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file withthe Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)